Investors & Media

Dec 9, 2022 /

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Dec 9, 2022 / Dec 9, 2022 /

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Recent News

11/14/22

BELLUS Health Reports Third Quarter 2022 Financial Results and Business Highlights
- Initiated CALM Phase 3 program with topline data expected for CALM-1 and CALM-2 in the second half of 2024 and 2025, respectively - - Ended third quarter 2022 with US$364.4 million in cash, cash equivalents and short-term investments; Cash runway extended to the second half of 2025 and through...
Read More
11/10/22

BELLUS Health to Participate in Two Upcoming Healthcare Investor Conferences
LAVAL, Quebec --(BUSINESS WIRE)--Nov. 10, 2022-- BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough (“RCC”) and other cough hypersensitivity indications,...
Read More
10/10/22

BELLUS Health to Present Clinical Data from Phase 2b SOOTHE Trial of BLU-5937 at the CHEST Annual Meeting
LAVAL, Quebec --(BUSINESS WIRE)--Oct. 10, 2022-- BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough (“RCC”) and other cough hypersensitivity indications,...
Read More